Trial Profile
A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 05 Oct 2020 Status changed from recruiting to completed.
- 22 Oct 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 22 Oct 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.